122 related articles for article (PubMed ID: 27134571)
1. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition.
Hayashi M; Madokoro H; Yamada K; Nishida H; Morimoto C; Sakamoto M; Yamada T
Cancer Cell Int; 2016; 16():35. PubMed ID: 27134571
[TBL] [Abstract][Full Text] [Related]
2. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
Yamada K; Hayashi M; Madokoro H; Nishida H; Du W; Ohnuma K; Sakamoto M; Morimoto C; Yamada T
PLoS One; 2013; 8(4):e62304. PubMed ID: 23638030
[TBL] [Abstract][Full Text] [Related]
3. Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.
Hayashi M; Madokoro H; Yamada K; Nishida H; Morimoto C; Sakamoto M; Yanagawa H; Yamada T
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398954
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Takeda M; Ohe Y; Horinouchi H; Hida T; Shimizu J; Seto T; Nosaki K; Kishimoto T; Miyashita I; Yamada M; Kaneko Y; Morimoto C; Nakagawa K
Lung Cancer; 2019 Nov; 137():64-70. PubMed ID: 31557561
[TBL] [Abstract][Full Text] [Related]
5. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Angevin E; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Vielh P; Farace F; Valleix F; Podoll T; Kuramochi Y; Miyashita I; Hosono O; Dang NH; Ohnuma K; Yamada T; Kaneko Y; Morimoto C
Br J Cancer; 2017 Apr; 116(9):1126-1134. PubMed ID: 28291776
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.
Nakagawa K; Kijima T; Okada M; Morise M; Kato M; Hirano K; Fujimoto N; Takenoyama M; Yokouchi H; Ohe Y; Hida T; Aoe K; Kishimoto T; Hirokawa M; Matsuki H; Kaneko Y; Yamada T; Morimoto C; Takeda M
JTO Clin Res Rep; 2021 Jun; 2(6):100178. PubMed ID: 34590026
[TBL] [Abstract][Full Text] [Related]
7. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
[TBL] [Abstract][Full Text] [Related]
8. [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule].
Morimoto C; Ohnuma K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):855-62. PubMed ID: 27431629
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y; Hatano R; Hirota N; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Valleix F; Podoll T; Umezawa Y; Takao S; Iwata S; Hosono O; Taguchi T; Yamada T; Dang NH; Ohnuma K; Angevin E; Morimoto C
Biomark Res; 2021 Mar; 9(1):21. PubMed ID: 33757558
[TBL] [Abstract][Full Text] [Related]
10. Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Hatano R; Yamada T; Matsuoka S; Iwata S; Yamazaki H; Komiya E; Okamoto T; Dang NH; Ohnuma K; Morimoto C
Diagn Pathol; 2014 Feb; 9():30. PubMed ID: 24502396
[TBL] [Abstract][Full Text] [Related]
11. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
Hatano R; Yamada T; Madokoro H; Otsuka H; Komiya E; Itoh T; Narita Y; Iwata S; Yamazaki H; Matsuoka S; Dang NH; Ohnuma K; Morimoto C
PLoS One; 2019; 14(6):e0218330. PubMed ID: 31194830
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
[TBL] [Abstract][Full Text] [Related]
13. Transient suppression of nuclear Cdc2 activity in response to ionizing radiation.
Kim MJ; Lee JY; Lee SJ
Oncol Rep; 2008 May; 19(5):1323-9. PubMed ID: 18425394
[TBL] [Abstract][Full Text] [Related]
14. A p21(waf1)-independent pathway for inhibitory phosphorylation of cyclin-dependent kinase p34(cdc2) and concomitant G(2)/M arrest by the chemopreventive flavonoid apigenin.
McVean M; Weinberg WC; Pelling JC
Mol Carcinog; 2002 Jan; 33(1):36-43. PubMed ID: 11807956
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Amatya VJ; Takeshima Y; Kushitani K; Yamada T; Morimoto C; Inai K
Oncol Rep; 2011 Dec; 26(6):1369-75. PubMed ID: 21894438
[TBL] [Abstract][Full Text] [Related]
16. [Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
Morimoto C; Ohnuma K
Nihon Rinsho; 2012 Dec; 70(12):2177-82. PubMed ID: 23259393
[TBL] [Abstract][Full Text] [Related]
17. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.
Park WH; Seol JG; Kim ES; Hyun JM; Jung CW; Lee CC; Kim BK; Lee YY
Cancer Res; 2000 Jun; 60(11):3065-71. PubMed ID: 10850458
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of SL4 against breast cancer cells: induction of G
Wang LH; Jiang XR; Chen GL; Guo W; Zhang JY; Cui LJ; Li HH; Li M; Liu X; Yang JY; Wu CF
Sci Rep; 2016 Nov; 6():36486. PubMed ID: 27819344
[TBL] [Abstract][Full Text] [Related]
20. A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways.
Ke JY; Zhang W; Gong RS; Cen WJ; Huang HQ; Li YR; Kong WD; Jiang JW
Tumour Biol; 2016 Nov; 37(11):14863-14872. PubMed ID: 27644244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
